Search

1 to 10 of 168
Sort by

Library Entry
Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis

Hypophysitis is a well-recognized immune-related adverse event in patients treated with immune checkpoint inhibitors for cancer. Some anterior pituitary hormones may recover; however, secondary adrenal insufficiency is usually permanent. This case documents an unusual recovery from secondary...



Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2019

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2018

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2017

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2016

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with nationally...


Library Entry
Living With Melanoma Symposium – An AIM at Melanoma Foundation Resource – 2015

One cannot help but feel scared and overwhelmed after receiving a melanoma diagnosis. The challenges that patients, caregivers, family members, and friends face can be daunting and can continue even after treatment has ended. Beginning in 2010, AIM at Melanoma began partnering with...


Library Entry
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy

High response rates of metastatic melanoma have been reported upon immune checkpoint inhibition by PD-1 blockade alone or in combination with CTLA-4 inhibitors. However, the majority of patients with a primary resistance to anti-PD-1 monotherapy is also refractory to a subsequent combined...


Library Entry
Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Tumor Mutation Burden (TMB) is a debated predictor for response to checkpoint inhibitors and early measurement of ctDNA can help to detect treatment failure to immunotherapy in selected melanoma patients. However, it has not yet been clarified how TMB and ctDNA can be used to estimate response...